Advertisement
PCRX vs TEVA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCRX is a StrongBuy and TEVA is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PCRX’s FA Score shows that 0 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).
- PCRX’s FA Score: 0 green, 5 red.
- TEVA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PCRX’s TA Score shows that 4 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).
- PCRX’s TA Score: 4 bullish, 5 bearish.
- TEVA’s TA Score: 4 bullish, 5 bearish.
Price Growth
PCRX (@Pharmaceuticals: Generic) experienced а +9.76% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +4.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.61%. For the same industry, the average monthly price growth was +11.38%, and the average quarterly price growth was +81.44%.
Reported Earning Dates
PCRX is expected to report earnings on Oct 30, 2025.
TEVA is expected to report earnings on Nov 06, 2025.
Industries' Descriptions
@Pharmaceuticals: Generic (+5.61% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| PCRX | TEVA | PCRX / TEVA | |
| Capitalization | 1.13B | 18.8B | 6% |
| EBITDA | 28M | 1.9B | 1% |
| Gain YTD | 33.652 | -25.499 | -132% |
| P/E Ratio | 12.90 | N/A | - |
| Revenue | 703M | 16.6B | 4% |
| Total Cash | 494M | 2.16B | 23% |
| Total Debt | 636M | 17.5B | 4% |
PCRX | TEVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 70 | |
SMR RATING 1..100 | 94 | 92 | |
PRICE GROWTH RATING 1..100 | 41 | 59 | |
P/E GROWTH RATING 1..100 | 100 | 12 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCRX's Valuation (57) in the Pharmaceuticals Other industry is in the same range as TEVA (74) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's Profit vs Risk Rating (70) in the Pharmaceuticals Generic industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to PCRX’s over the last 12 months.
TEVA's SMR Rating (92) in the Pharmaceuticals Generic industry is in the same range as PCRX (94) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to PCRX’s over the last 12 months.
PCRX's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as TEVA (59) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's P/E Growth Rating (12) in the Pharmaceuticals Generic industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than PCRX’s over the last 12 months.
| PCRX | TEVA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | N/A |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 73% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 58% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 67% |
| Advances ODDS (%) | 5 days ago 68% | 1 day ago 71% |
| Declines ODDS (%) | 7 days ago 78% | 12 days ago 73% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 58% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| WRND | 31.14 | N/A | N/A |
| NYLI Global Equity R&D Leaders ETF | |||
| HEJD | 26.91 | N/A | N/A |
| VictoryShares Hedged Equity Income ETF | |||
| UNOV | 36.73 | -0.01 | -0.01% |
| Innovator US Equity Ultra Buffer ETF Nov | |||
| EQTY | 25.53 | -0.11 | -0.42% |
| Kovitz Core Equity ETF | |||
| CWEB | 41.82 | -0.72 | -1.69% |
| Direxion Dly CSI CHN Itnet Bull 2X Shrs | |||
PCRX and
Correlation & Price change
A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.
| Ticker / NAME | Correlation To PCRX | 1D Price Change % | ||
|---|---|---|---|---|
| PCRX | 100% | N/A | ||
| ELAN - PCRX | 32% Poorly correlated | +2.58% | ||
| TEVA - PCRX | 28% Poorly correlated | +0.31% | ||
| ACET - PCRX | 27% Poorly correlated | -3.96% | ||
| SNDL - PCRX | 26% Poorly correlated | +19.64% | ||
| NBIX - PCRX | 25% Poorly correlated | -0.84% | ||
More | ||||
TEVA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.
| Ticker / NAME | Correlation To TEVA | 1D Price Change % | ||
|---|---|---|---|---|
| TEVA | 100% | +0.31% | ||
| AMRX - TEVA | 38% Loosely correlated | +3.63% | ||
| ELAN - TEVA | 31% Poorly correlated | +2.58% | ||
| VTRS - TEVA | 31% Poorly correlated | +1.65% | ||
| CGC - TEVA | 26% Poorly correlated | +26.11% | ||
| SNDL - TEVA | 26% Poorly correlated | +19.64% | ||
More | ||||